JP2020505425A - 癌治療 - Google Patents

癌治療 Download PDF

Info

Publication number
JP2020505425A
JP2020505425A JP2019541398A JP2019541398A JP2020505425A JP 2020505425 A JP2020505425 A JP 2020505425A JP 2019541398 A JP2019541398 A JP 2019541398A JP 2019541398 A JP2019541398 A JP 2019541398A JP 2020505425 A JP2020505425 A JP 2020505425A
Authority
JP
Japan
Prior art keywords
eldafitinib
treatment
serum phosphate
day
specifically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019541398A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505425A5 (https=
Inventor
スツイッケンズ，キム
ルイクソ，ジュアン，ホセ ペレス
ルイクソ，ジュアン，ホセ ペレス
ドュ，ポッレ，ピーター，マリー，ゼット．
アヴァドハニ，アンジャリ，ナラヤン．
ロリオット，ヨハン
シエフカー−ラドケ，アーリーン，オー．
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61094531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2020505425(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ヤンセン ファーマシューティカ エヌ．ベー．, ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Priority claimed from PCT/EP2018/052694 external-priority patent/WO2018141921A1/en
Publication of JP2020505425A publication Critical patent/JP2020505425A/ja
Publication of JP2020505425A5 publication Critical patent/JP2020505425A5/ja
Priority to JP2022189239A priority Critical patent/JP7668777B2/ja
Priority to JP2024196985A priority patent/JP2025024064A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Laminated Bodies (AREA)
  • Prostheses (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
JP2019541398A 2017-02-06 2018-02-02 癌治療 Withdrawn JP2020505425A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022189239A JP7668777B2 (ja) 2017-02-06 2022-11-28 癌治療
JP2024196985A JP2025024064A (ja) 2017-02-06 2024-11-11 癌治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762455211P 2017-02-06 2017-02-06
US62/455,211 2017-02-06
EP17209098.7 2017-12-20
EP17209098 2017-12-20
PCT/EP2018/052694 WO2018141921A1 (en) 2017-02-06 2018-02-02 Cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022189239A Division JP7668777B2 (ja) 2017-02-06 2022-11-28 癌治療

Publications (2)

Publication Number Publication Date
JP2020505425A true JP2020505425A (ja) 2020-02-20
JP2020505425A5 JP2020505425A5 (https=) 2021-03-18

Family

ID=61094531

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019541398A Withdrawn JP2020505425A (ja) 2017-02-06 2018-02-02 癌治療
JP2022189239A Active JP7668777B2 (ja) 2017-02-06 2022-11-28 癌治療
JP2024196985A Pending JP2025024064A (ja) 2017-02-06 2024-11-11 癌治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022189239A Active JP7668777B2 (ja) 2017-02-06 2022-11-28 癌治療
JP2024196985A Pending JP2025024064A (ja) 2017-02-06 2024-11-11 癌治療

Country Status (26)

Country Link
US (2) US11077106B2 (https=)
EP (2) EP4286005A3 (https=)
JP (3) JP2020505425A (https=)
KR (2) KR20250069693A (https=)
CN (1) CN110198716A (https=)
AU (2) AU2018216969B2 (https=)
BR (1) BR112019016043A2 (https=)
CA (1) CA3049737A1 (https=)
DK (1) DK3576740T3 (https=)
ES (1) ES2953005T3 (https=)
FI (1) FI3576740T3 (https=)
HR (1) HRP20230697T1 (https=)
HU (1) HUE062453T2 (https=)
IL (1) IL268463A (https=)
JO (1) JOP20190190B1 (https=)
LT (1) LT3576740T (https=)
MX (2) MX2019009304A (https=)
NZ (2) NZ796822A (https=)
PH (1) PH12019501885A1 (https=)
PL (1) PL3576740T3 (https=)
RS (1) RS64778B1 (https=)
SG (2) SG11201907199QA (https=)
SI (1) SI3576740T1 (https=)
SM (1) SMT202300233T1 (https=)
TW (1) TWI874925B (https=)
UA (1) UA126336C2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021201201A1 (ja) * 2020-04-03 2021-10-07 インタープロテイン株式会社 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物
JP2022527189A (ja) * 2019-03-29 2022-05-31 ヤンセン ファーマシューティカ エヌ．ベー． 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200208224A1 (en) * 2014-09-26 2020-07-02 Janssen Pharmaceutica Nv Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
EP4063516A1 (en) 2014-09-26 2022-09-28 Janssen Pharmaceutica NV Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
AU2018216969B2 (en) * 2017-02-06 2024-04-11 Janssen Pharmaceutica Nv Cancer treatment
PH12021551949A1 (en) * 2019-02-12 2022-07-18 Janssen Pharmaceutica Nv Cancer treatment
SG11202109854RA (en) * 2019-03-29 2021-10-28 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
MX2022009905A (es) * 2020-02-12 2022-08-25 Janssen Pharmaceutica Nv Inhibidores de la tirosina?cinasa fgfr para el tratamiento del cancer de vejiga sin invasion muscular de riesgo alto.
IL324823A (en) * 2023-05-24 2026-01-01 Janssen Pharmaceutica Nv Treatment of locally advanced or metastatic urothelial carcinoma with ardefinitiv

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016161239A1 (en) * 2015-04-03 2016-10-06 Astex Therapeutics Limited Fgfr/pd-1 combination therapy for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI719960B (zh) * 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
AU2018216969B2 (en) * 2017-02-06 2024-04-11 Janssen Pharmaceutica Nv Cancer treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016161239A1 (en) * 2015-04-03 2016-10-06 Astex Therapeutics Limited Fgfr/pd-1 combination therapy for the treatment of cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARCHIVE HISTORY FOR NCT02365597, JPN6021047115, 21 January 2017 (2017-01-21), ISSN: 0004834168 *
J. CLIN. ONCOL., vol. 33, no. 30, JPN6021047113, 2015, pages 3401 - 3408, ISSN: 0004834170 *
J. GASTROINTEST. ONCOL., vol. 7, no. 5, JPN6021047114, 2016, pages 789 - 796, ISSN: 0004834169 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022527189A (ja) * 2019-03-29 2022-05-31 ヤンセン ファーマシューティカ エヌ．ベー． 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
JP7747521B2 (ja) 2019-03-29 2025-10-01 ヤンセン ファーマシューティカ エヌ．ベー． 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
WO2021201201A1 (ja) * 2020-04-03 2021-10-07 インタープロテイン株式会社 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物

Also Published As

Publication number Publication date
IL268463A (en) 2019-09-26
PL3576740T3 (pl) 2023-09-11
NZ755301A (en) 2025-12-19
MX2019009304A (es) 2019-09-19
BR112019016043A2 (pt) 2020-03-31
EP4286005A2 (en) 2023-12-06
ES2953005T3 (es) 2023-11-07
DK3576740T3 (da) 2023-07-24
NZ796822A (en) 2025-12-19
HUE062453T2 (hu) 2023-11-28
SI3576740T1 (sl) 2023-10-30
KR20250069693A (ko) 2025-05-19
TW202402290A (zh) 2024-01-16
CN110198716A (zh) 2019-09-03
US20220110935A1 (en) 2022-04-14
US11077106B2 (en) 2021-08-03
JP7668777B2 (ja) 2025-04-25
EP3576740A1 (en) 2019-12-11
EP3576740B1 (en) 2023-06-14
SMT202300233T1 (it) 2023-09-06
SG10202105110VA (en) 2021-06-29
HRP20230697T1 (hr) 2023-10-13
TWI874925B (zh) 2025-03-01
AU2018216969A1 (en) 2019-07-25
KR20190110581A (ko) 2019-09-30
AU2024201871A1 (en) 2024-04-11
AU2024201871B2 (en) 2026-02-26
RS64778B1 (sr) 2023-11-30
AU2018216969B2 (en) 2024-04-11
LT3576740T (lt) 2023-08-10
JP2025024064A (ja) 2025-02-19
JP2023022190A (ja) 2023-02-14
UA126336C2 (uk) 2022-09-21
MX2022007955A (es) 2022-07-27
JOP20190190A1 (ar) 2019-08-04
SG11201907199QA (en) 2019-09-27
US20200022976A1 (en) 2020-01-23
EP4286005A3 (en) 2024-03-06
CA3049737A1 (en) 2018-08-09
FI3576740T3 (fi) 2023-08-31
JOP20190190B1 (ar) 2024-04-18
PH12019501885A1 (en) 2020-06-29

Similar Documents

Publication Publication Date Title
JP7668777B2 (ja) 癌治療
TWI798199B (zh) 癌症治療
US20210154198A1 (en) Combination therapy involving diaryl macrocyclic compounds
CN109819649B (zh) 氨基嘌呤化合物的固体形式及其使用方法
JP2018529698A (ja) Ｅｚｈ２阻害剤により卵巣の悪性ラブドイド腫瘍（ｍｒｔｏ）／高カルシウム血症型の卵巣の小細胞癌（ｓｃｃｏｈｔ）を処置するための方法
JP2026016402A (ja) 癌治療
CN109073650A (zh) 包括对西地尼布进行固定的间歇给药的方法
JP2025156297A (ja) 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
HK40103983A (en) Cancer treatment
HK40013982A (en) Cancer treatment
EA051616B1 (ru) Лечение рака
EA052711B1 (ru) Лечение рака
HK40018978B (en) Cancer treatment
HK40018978A (en) Cancer treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210201

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221128

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221128

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221206

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221213

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20221223